截至2026年4月24日,Immuneering公司320毫克ITT人群观察到17.3个月中位总生存期——SEC文件披露

美股速递
Jun 02

根据一份提交给美国证券交易委员会的文件,截至2026年4月24日,生物技术公司Immuneering Corp在其320毫克剂量组的意向治疗人群中,观察到的中位总生存期达到了17.3个月。这一数据来源于公司正在进行的研究,并作为关键信息向监管机构进行了报备。该生存期数据是评估其候选疗法临床潜力的一个重要指标,反映了接受该剂量治疗的患者的总体生存时间中位数。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10